Leidos Holdings enters the back half of June under fresh analyst pressure, with a high-profile downgrade landing just as the stock extends a painful two-month slide.
BofA Securities cut its rating to Neutral from Buy on Tuesday, slashing its price target from $200 to $125. That move matters — it's the second downgrade from a bellwether name in less than three weeks. Jefferies made the same call on June 3, dropping from Buy to Hold and pulling its target from $185 to $140. The direction of travel across the Street is unmistakable: firms that were constructive on Leidos through 2025 are now stepping back. The consensus still shows ten Hold ratings against four Buys, with the mean target at $178 — well above the current $113.58, but that gap reflects targets set before this month's wave of cuts rather than fresh optimism. Citigroup maintained its Buy but lowered its target to $178 from $232 in May, while RBC held its Outperform but trimmed to $180. On balance, the Street is moving sideways, not forward.
The stock itself is down 8% on the week and off more than 8% over the past month, closing at $113.58 on Tuesday. Close peers felt pressure too, but not nearly as sharply. BAH fell 6.3% over the same period and dropped 4.6%, while lost 3.9%. Leidos is underperforming its entire defense IT peer group — and that gap widened this week specifically around the BofA action.
The short positioning picture is more complex than the price action implies. Short interest climbed 45% over the past month, reaching 3.8% of the free float, a meaningful build. But the lending market is not under stress. Availability is extremely loose — there are roughly 38 shares available to borrow for every one currently lent out, putting availability at around 3,797%. Cost to borrow remains negligible at 0.36%, well below anything that would indicate squeeze conditions. Shorts are building, but they are doing so cheaply and without friction. The short score is a moderate 38, having dipped from a recent peak of 40 earlier this week — suggesting the short-side pressure is building gradually rather than accelerating.
Options positioning is the data point most at odds with the bearish narrative. The put/call ratio has collapsed to 0.60, nearly two standard deviations below its 20-day average of 0.88. That is close to the lowest options defensive positioning seen in the past year, with only the 52-week low of 0.40 below it. When a stock falls 8% in a week and shorts add positions, but options traders simultaneously shed put protection, the signals diverge sharply. One possible read: options traders who hedged into the May earnings miss have since unwound those positions, leaving the options market looking unusually light on downside coverage even as fundamental concerns persist.
The May earnings print is the event that set this sequence in motion. Leidos fell 9.3% on the day of results and another 14% over the following week — its worst post-earnings reaction in recent memory. The bear case centres on the VA medical exam contract, which carries above-average margins, and the risk that any reduction there flows directly to the bottom line. The bull case points to a diversified contract base across defence, intelligence, and health, plus a pipeline of IT modernisation work that should be resilient to near-term budget noise. Valuation has compressed accordingly: the PE multiple now sits at 8.9x, down almost a full turn over the past month, and EV/EBITDA has contracted to 7.3x. On an EV/EBIT basis, Leidos ranks in the 88th percentile for attractiveness across the ORTEX universe — cheap, but cheapening for a reason.
The next scheduled earnings event is August 4, which means the next six weeks will be dominated by any news flow around federal budget decisions, contract renewals, and whether the VA programme headwinds have stabilised — those are the data points to watch as the Street recalibrates its targets.
See the live data behind this article on ORTEX.
Open LDOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
